articlePotential blockbuster drugs to watch in 202510 January 2025 | By European Pharmaceutical ReviewEleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
newsGLP-1 receptor agonists aid broader outcomes in kidney disease, major analysis finds26 November 2024 | By Catherine Eckford (European Pharmaceutical Review)The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
newsFrom biologics to small molecules – the shift in biopharma’s revenue growth31 July 2024 | By Catherine Eckford (European Pharmaceutical Review)Biopharma companies that experienced strong revenue growth due to COVID-19 drug sales have been overtaken by companies that developed obesity drugs in 2023, GlobalData suggests.
newsSemaglutide could provide novel dual benefit in diabetes and kidney disease8 March 2024 | By Catherine Eckford (European Pharmaceutical Review)The new data suggests Novo Nordisk’s small molecule treatment semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD).
newsNew approach for synthesis of oligonucleotide conjugates14 December 2023 | By Caroline Peachey (European Pharmaceutical Review)Researchers from Aarhus University and Novo Nordisk have discovered a new synthesis method for oligonucleotide conjugates, marking a step forward in development of more targeted RNA medicines.
newsCounterfeit diabetes pens identified in EU and UK19 October 2023 | By Catherine Eckford (European Pharmaceutical Review)Following shortages of the diabetes medicine Ozempic (semaglutide), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have confirmed cases of falsely labelled pre-filled pens at UK and EU wholesalers.
newsCPHI Pharma Awards 2023 finalists announced15 September 2023 | By CPhIThe finalists for CPHI’s Pharma Awards 2023 across twelve categories for innovation, manufacturing, sustainability, best start-up initiative and breakthrough digital technologies have been announced.
newsSemaglutide weight loss injection launched in UK5 September 2023 | By Catherine Eckford (European Pharmaceutical Review)Following Novo Nordisk’s announcement that its Wegovy injection for obesity demonstrated a 20 percent reduction in major adverse cardiovascular outcomes, the pharma giant has launched the semaglutide treatment in the UK.
newsSemaglutide demonstrates cardiovascular benefit8 August 2023 | By Catherine Eckford (European Pharmaceutical Review)In Novo Nordisk’s landmark trial for cardiovascular outcomes, semaglutide 2.4mg has potential to change how obesity is regarded and treated, headline data suggests.
newsMCAP for top bio/pharma companies reached $3.4 trillion in 20211 February 2022 | By Hannah Balfour (European Pharmaceutical Review)Market capitalisation (MCAP) for the top bio/pharma companies grew 24.9 percent in 2021, with BioNTech and Moderna entering the top 20 for the first time.
articleDiabetes and obesity: treatment and trials update8 March 2021 | By Hannah Balfour (European Pharmaceutical Review)European Pharmaceutical Review reports on some of the latest developments in treatments for type 2 diabetes and obesity.
newsSemaglutide: “a significant advance in the treatment of obesity,” say scientists11 February 2021 | By Hannah Balfour (European Pharmaceutical Review)After 75 percent of obese patients treated with semaglutide lost at least 10 percent of their body weight, the drug has been submitted for regulatory approval in the UK, Europe and US.
newsSemaglutide may help people with obesity lose weight20 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight...
newsOral semaglutide shows promise for type 2 diabetes17 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes...
